利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.028 秒)

    Methods of Determining Patient Response By Measurement of HER-2 Expression
    4.
    发明申请
    Methods of Determining Patient Response By Measurement of HER-2 Expression 审中-公开
    通过测量HER-2表达来确定患者反应的方法

    公开(公告)号：US20100233732A1

    公开(公告)日：2010-09-16

    申请号：US12688766

    申请日：2010-01-15

    申请人： Michael Bates ,  Jennifer W. Cook ,  Gundo Diedrich ,  Laurie Goodman ,  Ali Mukherjee ,  Gordon Parry ,  Jeff Sperinde ,  Stephen J. Williams

    发明人： Michael Bates ,  Jennifer W. Cook ,  Gundo Diedrich ,  Laurie Goodman ,  Ali Mukherjee ,  Gordon Parry ,  Jeff Sperinde ,  Stephen J. Williams

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57415 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

    摘要： Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

    摘要翻译： 提供了用于确定或以其他方式评估患者对治疗，特别是癌症治疗的反应的方法。 这些方法包括单独或与其他生物标志物（如HER3标记物）结合存在或不存在HER2标记物的样品分析。 在某些实例中，可以通过首先确定HER2阳性患者，然后通过使用第二生物标志物（例如HER3标记）的存在或不存在进一步分层来确定进展的可能时间。 另外，数据可用于跟踪患者对治疗方案的反应，评估使用特定团治疗患者的预期成功率，确定治疗方案的效果或为了分类患者以创建均质组 进行临床试验。

    HER2 DIAGNOSTIC METHODS
    7.
    发明申请
    HER2 DIAGNOSTIC METHODS 有权
    HER2诊断方法

    公开(公告)号：US20090191559A1

    公开(公告)日：2009-07-30

    申请号：US12340436

    申请日：2008-12-19

    申请人： Weidong Huang ,  Jeff Sperinde ,  Michael Bates ,  Colombe Chappey

    发明人： Weidong Huang ,  Jeff Sperinde ,  Michael Bates ,  Colombe Chappey

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  G01N33/574

    CPC分类号： G01N33/574 ,  G01N33/57415 ,  G01N2800/52

    摘要： In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

    摘要翻译： 在某些方面，本发明提供用于确定Her-2阳性癌症是否可能对Her2-作用剂的治疗有反应和/或是否具有Her-2阳性癌症的患者可能具有慢的疾病的方法 进步。 在其它方面，本发明涉及用于确定具有Her-2阳性癌症的受试者是否不太可能响应除了Her2作用剂之外的至少一种化学治疗剂的治疗和/或患者是否具有 一个Her-2阳性的癌症很可能有一个快速的疾病进展。

    Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis
    9.
    发明申请
    Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis 审中-公开
    检测内皮细胞激活作为血管发生的替代标记物

    公开(公告)号：US20110275096A1

    公开(公告)日：2011-11-10

    申请号：US13103509

    申请日：2011-05-09

    申请人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

    发明人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

    IPC分类号： G01N33/566 ,  G01N33/53

    CPC分类号： G01N33/5041 ,  G01N33/5064 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2800/52 ,  Y10S436/824

    摘要： Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

    摘要翻译： 提供了方法，组合物和试剂盒，用于通过敏感，直接检测分子水平的内皮细胞活化来评估血管发生。 通常，通过测量参与内皮细胞中特异性血管生成信号传导途径的细胞成分及其蛋白质复合物的水平来检测内皮细胞的活化。 该方法可以用于评估与不期望的血管生成相关的疾病的状态，例如发展疾病的可能性，疾病的存在或不存在，疾病的预后以及对特定抗血管生成疗法的反应或抗性的可能性。 该方法还可用于指导针对特定血管生成信号通路的有效治疗方案的设计，以及与不期望的血管发生相关的疾病或病症的治疗干预。

    Detection of activation of endothelial cells as surrogate marker for angiogenesis
    10.
    发明授权
    Detection of activation of endothelial cells as surrogate marker for angiogenesis 有权
    内皮细胞活化检测作为血管发生的替代标志物

    公开(公告)号：US07939267B2

    公开(公告)日：2011-05-10

    申请号：US11267870

    申请日：2005-11-03

    申请人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

    发明人： Sean C. Moore ,  Sharat Singh ,  Hossein Salimi-Moosavi ,  Liching Cao ,  Jeff Sperinde

    IPC分类号： G01N33/53 ,  G01N33/566 ,  G01N33/58 ,  G01N33/567 ,  G01N33/535

    CPC分类号： G01N33/5041 ,  G01N33/5064 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2800/52 ,  Y10S436/824

    摘要： Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

    摘要翻译： 提供了方法，组合物和试剂盒，用于通过敏感，直接检测分子水平的内皮细胞活化来评估血管发生。 通常，通过测量参与内皮细胞中特异性血管生成信号传导途径的细胞成分及其蛋白质复合物的水平来检测内皮细胞的活化。 该方法可以用于评估与不期望的血管生成相关的疾病的状态，例如发展疾病的可能性，疾病的存在或不存在，疾病的预后以及对特定抗血管生成疗法的反应或抗性的可能性。 该方法还可用于指导针对特定血管生成信号通路的有效治疗方案的设计，以及与不期望的血管发生相关的疾病或病症的治疗干预。